An All-in-One Nanomedicine Consisting of CRISPR-Cas9 and an Autoantigen Peptide for Restoring Specific Immune Tolerance
Ying-Li Luo,Li-Fang Liang,Yun-Jiu Gan,Jing Liu,Yue Zhang,Ya-Nan Fan,Gui Zhao,Anna Czarna,Zi-Dong Lu,Xiao-Jiao Du,Song Shen,Cong-Fei Xu,Zhe-Xiong Lian,Jun Wang
DOI: https://doi.org/10.1021/acsami.0c10885
2020-10-19
Abstract:Nanotechnology has shown great promise in treating diverse diseases. However, developing nanomedicines that can cure autoimmune diseases without causing systemic immunosuppression is still quite challenging. Herein, we propose an all-in-one nanomedicine comprising an autoantigen peptide and CRISPR-Cas9 to restore specific immune tolerance by engineering dendritic cells (DCs) into a tolerogenic phenotype, which can expand autoantigen-specific regulatory T (Treg) cells. In brief, we utilized cationic lipid-assisted poly(ethylene glycol)-<i>b</i>-poly(lactide-<i>co</i>-glycolide) (PEG-PLGA) nanoparticles to simultaneously encapsulate an autoimmune diabetes-relevant peptide (2.5mi), a CRISPR-Cas9 plasmid (pCas9), and three guide RNAs (gRNAs) targeting costimulatory molecules (CD80, CD86, and CD40). We demonstrated that the all-in-one nanomedicine was able to effectively codeliver these components into DCs, followed by simultaneous disruption of the three costimulatory molecules and presentation of the 2.5mi peptide on the genome-edited DCs. The resulting tolerogenic DCs triggered the generation and expansion of autoantigen-specific Treg cells by presenting the 2.5mi peptide to CD4<sup>+</sup> T cells in the absence of costimulatory signals. Using autoimmune type 1 diabetes (T1D) as a typical disease model, we demonstrated that our nanomedicine prevented autoimmunity to islet components and inhibited T1D development. Our all-in-one nanomedicine achieved codelivery of CRISPR-Cas9 and the peptide to DCs and could be easily applied to other autoimmune diseases by substitution of different autoantigen peptides.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c10885?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c10885</a>.Characterization of the all-in-one CLAN<sub>pCas9/gCD80,86,40/2.5mi</sub>; stability of CLAN<sub>pCas9/gCD80,86,40/2.5mi</sub> in DMEM containing 10% FBS; original uncropped gel images of <a class="internalNav" href="#fig1">Figure </a><a class="internalNav" href="#fig1">1</a>D; representative mutated sequences in CD80, CD86, and CD40 genes of BMDCs transfected with CLAN<sub>pCas9/gCD80,86,40/2.5mi</sub>; original uncropped gel images of <a class="internalNav" href="#fig3">Figure </a><a class="internalNav" href="#fig3">3</a>C; representative flow cytometry pictures of <a class="internalNav" href="#fig4">Figure </a><a class="internalNav" href="#fig4">4</a>F,G; representative flow cytometry pictures of <a class="internalNav" href="#fig4">Figure </a><a class="internalNav" href="#fig4">4</a>H; oligos used for cloning gRNA expression vectors; oligos used for making template for IVT; and oligos used for T7E1 assay and indel sanger sequencing assay (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c10885/suppl_file/am0c10885_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology